NCT02138045已完成不适用
A Randomized, Double-blinded, Single-centre, Parallel-group, Placebo-controlled, Prospective Trial of Neuroprotective Effect of Liraglutide for Treatment of Diabetic Neuropathy.
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 1
- 主要终点
- Evoked brain potentials (using standard electroencephalographic brain imaging).
研究概览
简要总结
The purpose of this trial is to explore whether liraglutide has a long term effect on clinical symptoms and biomarkers in patients with diabetic neuropathy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Abile person of Northern European descent
- •Age between 18 to 65 years
- •A verified diagnosis of DM type 1 for minimum 2 years (HbA1C=7%)
- •Stable DM treatment (Treatment is considered stable when the patient has been treated with basal-bolus insulin, premixed insulin or continously infused insulin with an insulin dose considered stable by investigator for at least 3 months prior to screening.)
- •The participants must be able to read and understand Danish.
- •Peripheral diabetic neuropathy ensured by having abnormal nerve conduction velocity
- •BMI equal to or above 22
- •Personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.
- •Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests and other trial procedures.
排除标准
- •Diabetes mellitus type II
- •Estimated glomerular filtration rate (s-creatinin/eGRF) < 60 ml/min/1.37m2
- •Calcitonin > 25
- •HbA1c level < 7%
- •Patients with any clinically significant laboratory abnormalities, that in the opinion of the investigator may increase the risk associated with trial participation or may interfere with the interpretation of the trial results.
- •Patients on GLP-1 receptor agonist treatment (exenatide, liraglutide or others) or pramlintide or any DPP-4 inhibitor within 3 months prior to screening.
- •Other neurological and/or psychiatric disease
- •Treatment of other endocrinological disease except hypothyreosis
- •Malignant neoplasms requiring chemotherapy, surgery, radiation or palliative care in the previous 5 years.
- •Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma.
- •Personal history of non-familial medullary thyroid carcinoma
- •Known abuse or alcohol and/or medicine (Alcohol use in accordance with the recommendations by the Danish Health and Medicines Authority are allowed).
- •Known allergy to liraglutide.
- •Participation in other clinical trials less than 3 months prior to inclusion
- •Female patients who are pregnant or lactating, or intend to become pregnant and male patients who intend to father a child during course of the study.
- •In women, a serum pregnancy test will be conducted at baseline based on h-CG in the blood. The investigator will have to ensure that fertile female patients use a safe contraception method during the study and for at least 15 hours after termination of the study medication period.
研究组 & 干预措施
Placebo treatment
Placebo Comparator
Placebo solution will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:
First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day.
干预措施: Placebo treatment (Drug)
Liraglutide treatment
Active Comparator
Liraglutide will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:
First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day.
干预措施: Liraglutide treatment (Drug)
结局指标
主要结局
Evoked brain potentials (using standard electroencephalographic brain imaging).
时间窗: After 6 months of treatment with Liraglutide
RIII withdrawal reflex activity (using standard electromyography)
时间窗: After 6 months of treatment with Liraglutide
次要结局
- Quantitive sensory testing of pressure algometry in muscle(After 6 months of treatment with Liraglutide)
- Profile of inflammatory cytokines including IL-beta, TNF-alfa, IL6, MCP-1 and specific markers sCD163, sMR, neopterin and HO-1.(After 6 months of treatment with Liraglutide)
- Microstructural brain neurodegeneration (assessed by diffuse tensor imaging)(After 6 months of treatment with Liraglutide)
- Variety in day/night blood pressure(After 6 months of treatment with Liraglutide)
- Resting brain activity (spectral analysis of resting brain activity)(After 6 months of treatment with Liraglutide)
- Gut transit assessed by SmartPill (pH, pressure and transit in stomach, small and large intestine)(After 6 months of treatment with Liraglutide)
- Capacity of descending pain inhibition induced by a cold pressor test (2C in 120 sec)(After 6 months of treatment with Liraglutide)
- Self assessed symptomatology (Michigan neuropathy screening tool, Quality of life (SF-36), Pain catastrophizing scale (PCS) and self-assessed gastro-intestinal symptoms (PAGI-SYM))(After 6 months of treatment with Liraglutide)
- OCT(After 6 months of treatment with Liraglutide)
- Heart rate variability/ alterations in simpatico-vagal balance (24 h Holter monitoring)(After 6 months of treatment with Liraglutide)
- Metabolic risk factors expressed as adipokines (adiponectin, leptin, resistin) and inflammatory cell markers(After 6 months of treatment with Liraglutide)
研究者
Asbjørn Mohr Drewes
Professor, MD, PhD
Aalborg University Hospital
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Liraglutide in Newly Onset Type 1 Diabetes.Diabetes Mellitus, Type 1NCT01879917Hvidovre University Hospital65
已完成
2 期
Safety and Efficacy of Liraglutide in Parkinson's DiseaseParkinson DiseaseNCT02953665Cedars-Sinai Medical Center63
已完成
不适用
Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily PracticeDiabetesDiabetes Mellitus, Type 2NCT02255266Novo Nordisk A/S1,788
招募中
4 期
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)Type 2 Diabetes PatientsOverweight and ObesityHyperglycaemia (Diabetic)NCT03087032The First Affiliated Hospital of Xiamen University164
已完成
1 期
Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal WomenDiabetesDiabetes Mellitus, Type 2NCT01508858Novo Nordisk A/S21